Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
Complement factor H (CFH), an immune factor enhances osteoblast differentiation and correlates with bone density.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Li, Hu Huimin, Qiu Weimin, Shi Kaikai, Ditzel Nicholas, Figeac Florence, Taipaleenmaeki Hanna, Zhang Hanxiao, Li Sanen, Ding Ming, Yang Liu, Zhai Yuankun, Luo Zhuojin, Kong Xijian, Yang Lishang, Tao Jiuyuan, Ma Wei, Kowal Justyna Magdalena, Andersen Thomas Levin, Botto Marina, Kassem Moustapha
Аннотация
Complement factor H (CFH) is an immune regulator that inhibits the complement system. Here, we identify CFH as a secreted and regulated factor in human bone marrow skeletal stem cells (hBMSCs) culture during osteoblast (OB) differentiation. To explore its role in bone formation, we investigated the effects of CFH on OB differentiation and bone homeostasis. CFH-deficient hBMSCs exhibited impaired OB differentiation, whereas CFH overexpression or supplementation enhanced OB differentiation in hBMSCs. In vivo, CFH-deficient (CFH-/-) mice displayed reduced trabecular and cortical bone mass, decreased bone formation, and diminished bone strength. Primary CFH-/- mouse bone marrow MSCs (mBMSCs) showed reduced osteogenesis but enhanced osteoclast differentiation, consistent with lower serum levels of the bone formation marker P1NP and elevated bone resorption markers TRAPc and CTX-1. Furthermore, CFH-/- mice exhibited delayed fracture healing and accelerated bone loss following ovariectomy or high-fat diet feeding. Clinically, CFH levels in bone marrow plasma were negatively correlated with fracture risk in patients. Notably, plasma CFH levels were positively associated with bone mineral density (BMD) and were significantly reduced in patients with osteoporosis. These findings establish CFH as a key regulator of osteogenesis and bone homeostasis, with potential implications for bone-related disorders.